Market Overview

Barclays Raises Price Target on Herbalife to $94, Cites Buyback Plan, Business Model in China

Related HLF
Watch These 7 Huge Call Purchases In Friday Trade
The Bill Ackman Trade Isn't Performing Very Well Today
Herbalife FAQ Ignores FTC And Regulatory Risk (Seeking Alpha)

Meredith Alder of Barclays appeared optimistic on Herbalife (NYSE: HLF) shares in a research note Tuesday morning. The analyst boosted her price target from $78 to $94 while maintaining an Overweight rating.

Adler attributed the boosted price target to her assumption for a large buyback plan (to the tune of $1.5 billion in shares) from Herbalife this year and also related to the company's business model in China.

The Barclays analyst believes Herbalife's business in China will be "unique" and "tightly controlled." She appears confident the issues with Nu Skin (NYSE: NUS) will not affect Herbalife in a “material way."

Alder adjusted her 2014 EPS estimate from $5.65 to $6.27 in the note. The analyst consensus estimate currently sits at $5.76.

With Herbalife shares up 1.3 percent to $71.11 at last check, Alder's new price target represents potential upside of about 32 percent.

Latest Ratings for HLF

Apr 2016BarclaysTerminatesOverweightOverweight
Aug 2015Pivotal ResearchMaintainsBuy
May 2015Canaccord GenuityMaintainsBuy

View More Analyst Ratings for HLF
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Global Analyst Ratings


Related Articles (HLF + NUS)

View Comments and Join the Discussion!